Genfit S.A. (LON:0QT6)

London flag London · Delayed Price · Currency is GBP · Price in EUR
3.645
+0.091 (2.56%)
At close: Oct 29, 2025
2.56%
Market Cap158.21M
Revenue (ttm)38.68M
Net Income (ttm)-33.22M
Shares Outn/a
EPS (ttm)-0.70
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5
Average Volume9,271
Open3.680
Previous Close3.554
Day's Range3.644 - 3.680
52-Week Range2.700 - 5.600
Beta1.33
RSI53.19
Earnings DateDec 23, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 180
Stock Exchange London Stock Exchange
Ticker Symbol 0QT6
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.